Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer

Background Apatinib has shown outstanding value in the treatment of advanced gastric cancer (AGC). However, no biomarkers are available to select AGC patients who will benefit from apatinib. The aim present study was investigate association between p53 and Ki67 expression outcome treated with Methods From December 2015 2020, 92 were enrolled retrospectively evaluated. They given apatinib at a daily dose 500 or 250 mg every 4 weeks monitor clinical efficacy adverse events (AEs). Kaplan-Meier method used for survival analysis. Expression detected by immunohistochemistry (IHC) correlated survival. Results Among evaluable patients, objective response rate (ORR) disease control (DCR) 17.4% 79.3%, respectively, none them achieved CR, 16 PR (17.4%) (95% CI 9.8%-26.1%). Stable (SD) observed 57.6% 49.2%-69.9%) PD 21.7% 13.6%-31.3%). median progression free (mPFS) 122.7 ± 8.2 days, overall (mOS) 203.4 11.9 days. P53 35 (38.0%) high 34 (37.0%). There statistically significant inverse relationship ( P =0.014). Moreover, significantly OS =0.018), but had influence on OS. Conclusions showed promising efficiency well tolerated as second-line patients. p53-negative likely treatment; however, proteins impact